jcm-logo

Journal Browser

Journal Browser

Translational Immunology in Clinical Medicine: From Preclinical Insights to Therapeutic Impact

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology & Rheumatology".

Deadline for manuscript submissions: 25 March 2026 | Viewed by 758

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Interests: translational immunology;autoimmune disease; autoinflammatory disease; immune-mediated diseases; oncology; preclinical models; immune efficacy and safety; mechanism of action; Immunotoxicity assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will explore how advances in immunology are being translated into clinical practice, with a focus on immune-mediated diseases including autoimmune conditions, autoinflammatory syndromes, and cancers. As immunotherapies become increasingly central to the treatment of these disorders, there is a growing need for research that connects mechanistic understanding with clinical outcomes.
We welcome contributions that emphasize the clinical application of immunological insights—whether through the development of targeted therapies, identification of biomarkers for patient stratification, early-phase clinical trials, or real-world immune monitoring in treated populations. Studies should clearly demonstrate relevance to patient care, highlighting how immune mechanisms inform diagnostic decisions, therapeutic choices, or safety management.
Submissions may also include translational studies that bridge laboratory models with clinical data, provided they offer a direct line of sight to clinical utility. Humanized or patient-derived models, studies of immune-related adverse events, and analyses of immune signatures predictive of response or toxicity are especially encouraged.
By focusing on clinically meaningful immunology, this Special Issue aims to foster dialogue across disciplines and accelerate the integration of immune science into everyday medical practice.

Dr. Soheil Tavakolpour
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • translational immunology
  • autoimmune disease
  • autoinflammatory disease
  • immune-mediated diseases
  • oncology
  • preclinical models
  • immune efficacy and safety
  • mechanism of action
  • immunotoxicity assessment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 369 KB  
Review
Therapy with Immune Checkpoint Inhibitors for Solid Tumors in Patients with Preexisting Systemic Autoimmune Diseases
by Sara Elena Campos Ramírez, Pablo Gómez Mugarza, Paula Gomila Pons, Carmen Blanco Abad, María Pilar Felices Lobera, Sofía Elena Ruffini Egea, Pilar Rivero Sobreviela, Luis Gallart Caballero, Paula Morillas Martínez and Ana María Comín Orce
J. Clin. Med. 2025, 14(21), 7765; https://doi.org/10.3390/jcm14217765 - 1 Nov 2025
Viewed by 607
Abstract
Background: Patients with systemic autoimmune diseases (SAID) are at a higher risk of developing neoplasms, such as solid tumors and hematologic malignancies. Chronic stimulation of the immune system and some treatments for these diseases increase the risk of developing solid tumors. Also, it [...] Read more.
Background: Patients with systemic autoimmune diseases (SAID) are at a higher risk of developing neoplasms, such as solid tumors and hematologic malignancies. Chronic stimulation of the immune system and some treatments for these diseases increase the risk of developing solid tumors. Also, it is known that patients with SAID are usually excluded from clinical trials, but immune checkpoint inhibitors (ICI) are still used in these patients in everyday practice. Objectives: The objective of this article is to review the most up-to-date and robust literature on the use of ICI in patients with SAID for the treatment of solid tumors to obtain information on the efficacy and safety of these drugs in this subgroup of patients. Methods: A literature review was performed through international databases that included PubMed, Medline, Scopus, and Google Scholar. Articles about the use of ICI for solid tumors in patients with SAID were included; the types of articles included were retrospective studies, systematic reviews, and meta-analyses. A summarized descriptive analysis was performed about the efficacy and safety of ICI treatment for the main solid tumors (lung, melanoma, and other cutaneous malignancies, as well as renal and urothelial carcinoma). Conclusions: In general, it seems that ICI treatment is safe in patients with asymptomatic SAID. Close follow-up with a multidisciplinary team should be performed when ICI therapy is prescribed. A substitution of selective immunosuppressants (SIM) in place of nonselective immunosuppressants (NSIM) in asymptomatic patients is recommended before the initiation of ICI. Full article
Show Figures

Figure 1

Back to TopTop